# EasyPlus mini R2N Self Monitoring Glucose Test System 510(k) SUMMARY

A Submitter's information Company EPS Bio Technology Corp Address 2F, No 49-2, Lane 2, Guang Fu Rd , Sec 2 Hsinchu City, Taiwan, R O C Contact Name Mr Y C Lei, General Manager Phone 886-3-5752522 Fax 886-3-5752552

B Measured Glucose

C Type of Test Quantitative, electrochemical biosensor

Proprietary and Established Names EasyPlus mini R2N Self-Monitoring Blood Glucose Test System

E Common or Usual Name Glucose Test System

F Regulatory Information 1 Requlation section 21 CFR 862 1345, Glucose Test System 21 CFR 862 1660, Quality control materials (assayed and unassayed)

2 Classification Class II Class 1, reserved

3 Product code NBW, System Test, Blood Glucose, Over the Counter CGA, Glucose Oxidase, Glucose JJX, Single (Specified) Controls (assayed and Unassayed)

4 Panel Chemistry 75

# G Intended Use

1 Intended use(s) See Indications for Use below

2 Indication(s) for use

The EasyPlus mini R2N Self Monitoring Blood Glucose Test System The EasyPlus mini R2N Self Monitoring Blood Glucose Test System is intended for the quantitative measurement of glucose in fresh capillary whole blood samples drawn from the fingertips or forearm Testing is done outside the body (In Vitro diagnostic use) It is indicated for use at home (over the counter [OTC]) by persons with diabetes, or in clinical settings by healthcare professionals, as an aid to monitor the effectiveness of diabetes control

The EasyPlus mini R2N Meter   
The EasyPlus mini R2N Meter is intended for the quantitative measurement of glucose in fresh capillary whole blood samples drawn from the fingertips or forearm EasyPlus mini R2N Blood Glucose Test Strips must be used with the EasyPlus mini R2N Meter Testing is done outside the body (In Vitro diagnostic use)   
It is indicated for use at home (over the counter [OTC]) by persons with diabetes, or in clinical settings by healthcare professionals, as an aid to monitor the effectiveness of diabetes control The EasyPlus mini R2N Blood Glucose Test Strips   
The EasyPlus mini R2N Blood Glucose Test Strips , are intended for the   
quantitative measurement of glucose in fresh capillary whole blood samples drawn from the fingertips or forearm EasyPlus mini R2N Blood Glucose Test Strips must be used with the EasyPlus mini R2N Blood Glucose Meter Testing is done outside the body (In Vitro diagnostic use) They are indicated for use at home (over the counter [OTC]) by persons with diabetes, or in clinical settings by healthcare professionals, as an aid to monitor the effectiveness of diabetes control

The EasyPlus mini R2N Glucose Normal/High Control Solution For use with the EasyPlus mini R2N meter and EasyPlus mini R2N Blood Glucose Test Strips as a quality control check to verify the accuracy of blood glucose test results

# 3 Special conditions for use statement(s)

For Over-the-Counter use Not for use with newborns

Alternate site testing (AST) can only be used during steady-state blood glucose conditions AST (forearm) should only be performed under the following conditions

$\spadesuit$ Testing before a meal   
$\bullet$ In a fasting state   
$\bullet$ Two hours or more after a meal   
$\spadesuit$ Two hours or more after insulin dosing   
$\bullet$ Two hours after physical activity

# 4 Special instrument requirements

EasyPlus mini R2N Blood Glucose Meter

H Device Description

The EasyPlus mini R2N Self-Monitoring Blood Glucose System consists of the EasyPlus mini R2N Blood Glucose Meter, EasyPlus mini R2N Glucose Test Strips, Auto-Lancet Device, Check Strip and Control Solution (Please refer to the IFU for the product picture)

I Substantial Equivalence Information

1 Predicate device name(s) EasyPlus Self-Monitoring Blood Glucose System

2 Device Company EPS Bio Technology Corporation

3 Predicate 510(k) number(s) k061992

4 Comparison with predicate

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Detection method</td><td rowspan=1 colspan=1>Amperometry</td><td rowspan=1 colspan=1>Amperometry</td></tr><tr><td rowspan=1 colspan=1>Enzyme</td><td rowspan=1 colspan=1>Glucose oxidase(Aspergillus niger)</td><td rowspan=1 colspan=1>Glucose oxidase(Aspergillus niger)</td></tr><tr><td rowspan=1 colspan=1>Mediator</td><td rowspan=1 colspan=1>Potassium ferricyanide</td><td rowspan=1 colspan=1>Potassium ferricyanide</td></tr><tr><td rowspan=1 colspan=1>Electrode</td><td rowspan=1 colspan=1>Carbon electrode</td><td rowspan=1 colspan=1>Carbon electrode</td></tr><tr><td rowspan=1 colspan=1>Hematocrit range</td><td rowspan=1 colspan=1>20-60%</td><td rowspan=1 colspan=1>30-55%</td></tr><tr><td rowspan=1 colspan=1>Sample volume</td><td rowspan=1 colspan=1>≥06uL</td><td rowspan=1 colspan=1>≥20uL</td></tr><tr><td rowspan=1 colspan=1>Temperature range</td><td rowspan=1 colspan=1>10-40°C</td><td rowspan=1 colspan=1>10-40°C</td></tr><tr><td rowspan=1 colspan=1>Humidity range</td><td rowspan=1 colspan=1>RH ≤ 90%</td><td rowspan=1 colspan=1>RH ≤ 90%</td></tr><tr><td rowspan=1 colspan=1>Coding</td><td rowspan=1 colspan=1>One Code</td><td rowspan=1 colspan=1>Code card</td></tr><tr><td rowspan=1 colspan=1>Memory capability</td><td rowspan=1 colspan=1>480 tests with date andtime</td><td rowspan=1 colspan=1>100 tests with date andtime</td></tr><tr><td rowspan=1 colspan=1>Power</td><td rowspan=1 colspan=1>3V 2X CR2032 batteries</td><td rowspan=1 colspan=1>1 5V (AAA) batteries</td></tr><tr><td rowspan=1 colspan=1>Battery life</td><td rowspan=1 colspan=1>Approx 2000 tests</td><td rowspan=1 colspan=1>Approx 1000 tests</td></tr></table>

<table><tr><td rowspan=1 colspan=4>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=2>Predicate</td></tr><tr><td rowspan=1 colspan=1>Test range</td><td rowspan=1 colspan=1>20-600 mg/dL</td><td rowspan=1 colspan=2>30-550 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Test time</td><td rowspan=1 colspan=1>5 seconds</td><td rowspan=1 colspan=2>5 seconds</td></tr><tr><td rowspan=1 colspan=1>SizeLxWxH (inch)</td><td rowspan=1 colspan=1>3 5&quot;x 2 1&quot;x 0 97&quot;</td><td rowspan=1 colspan=2>3 2&quot;x 2&quot;x 0 7&quot;</td></tr><tr><td rowspan=1 colspan=1>Weight</td><td rowspan=1 colspan=1>2 05 oz (without batteries)</td><td rowspan=1 colspan=1>1 6 oz (without batteries)</td><td rowspan=1 colspan=1></td></tr></table>

# J Standard/Guidance Document Referenced (if applicable)

1 CLSI EP5-A, Precision Performance of Clinical Chemistry Devices   
2 CLSI EP6-A, Evaluation of the Lineanity of Quantitative Analytical Methods, Proposer Guideline   
3 CLSI EP7-A, Interference Testing in Clinical Chemistry, Proposed Guideline   
4 ISO 15197 2003, In Vitro Diagnostic Test Systems - Requirements for Blood Glucose Monitoring Test Systems for Self Managing Diabetes Mellitus   
5 IEC 60601-1-2, Medical Electrical Equipment - Part 1 General Requirement for Safety, Electromagnetic Compatibility - requrements and Tests   
6 IEC 61010-1, Safety Requirements for Electrical Equipment for Measurement, Control, and Laboratory Use - Part 1 General Requrrements   
7 IEC 60601-2-101, Safety Requirements For Electrical Equipment for Measurement, Control, and Laboratory Use - Part 2-101 Particular Requirements for In Vitro Diagnostic (IVD) Medical Equipment   
8 IEC 60068-2-64, Environmental Testing- Part 2 Test Methods- Test Fh Vibration, Broad-band Random (Digital Control) and Guidance   
9 IEC 61326 (2002-02) - (for reference), Electrical Equipment for Measurement Control, and Laboratory Use - EMC Requirements   
10 ISO 14971 2000, Medical Devices  Application of Risk Management to Medical Devices   
11 ISO 15223 2000, Medical Devices — Symbols to be Used With Medical Device Label Labeling, and Information to be Supplied   
12 EN 376 2002, Information Supplied by the Manufacturer With In Vitro Diagnostic Reagents for Self Testing   
13 ISO 10993-1, Biological Evaluation of Medical Devices - Part 1 Evaluation and Testing   
14 EN 13640 2002 Stablity Testing of In Vitro Diagnostic Reagents

# K Test Principle

The EasyPlus mini R2N Self-Monitoring Blood Glucose System employs a disposable dry reagent strip technology, based on the glucose oxidase method for glucose determination Each test strip features an electrode containing the enzyme glucose oxidase (Aspergillus niger) A blood sample is applied to the blood collection area at the tip of the strip and is automatically drawn into the reaction zone, where the glucose oxidase catalyzes the oxidation of glucose to produce gluconic acid During the reaction, a mediator transfers electrons to the electrode surface and generates a current The amount of the current is proportional to the amount of glucose present in the blood sample the glucose concentration is measured by the EasyPlus mini R2N Glucose Meter and displayed on the screen after 5 seconds

# L Performance Characteristics (if/when applicable)

1 Analytical performance a Precision/Reproducibility   
Within-run - The testing was used by venous blood, which comes with heparin blood   
collection tube Glucose was added to the blood to prepare 6 different levels of glucose

concentration for the testing The glucose concentration ranges were 20-50 mg/dL, 51- 110 mg/dL, 111-150 mg/dL, 151-250 mg/dL, 251-400 mg/dL, and $4 0 1 { \sim } 6 0 0 ~ \mathrm { m g / d L }$ For each testing range, 10 Meters, 10 PCs of test strips for each meter, and 2 lots of test strips were used $N = 1 0$ Meter $\tt { x 1 0 }$ tests x 2 lots $\tt { \tt = } 2 0 0 \mathrm { \mathrm { ~ \tt ~ } }$

<table><tr><td rowspan=2 colspan=1>Range (mg/dL)</td><td rowspan=2 colspan=1>N</td><td rowspan=1 colspan=3>Lot 021074801</td></tr><tr><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>SD(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>20~50 mg/dL</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>53 8</td><td rowspan=1 colspan=1>157</td><td rowspan=1 colspan=1>2 92%</td></tr><tr><td rowspan=1 colspan=1>51~110 mg/dL</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>76 0</td><td rowspan=1 colspan=1>1 98</td><td rowspan=1 colspan=1>2 61%</td></tr><tr><td rowspan=1 colspan=1>111~150 mg/dL</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>126 8</td><td rowspan=1 colspan=1>3 28</td><td rowspan=1 colspan=1>2 59%</td></tr><tr><td rowspan=1 colspan=1>151~250 mg/dL</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>214 6</td><td rowspan=1 colspan=1>7 05</td><td rowspan=1 colspan=1>3 29%</td></tr><tr><td rowspan=1 colspan=1>251~400 mg/dL</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>363 0</td><td rowspan=1 colspan=1>8 17</td><td rowspan=1 colspan=1>2 25%</td></tr><tr><td rowspan=1 colspan=1>401~600 mg/dL</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>561 6</td><td rowspan=1 colspan=1>12 39</td><td rowspan=1 colspan=1>221%</td></tr><tr><td rowspan=1 colspan=1>Normalcontrol solution</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>1116</td><td rowspan=1 colspan=1>3 92</td><td rowspan=1 colspan=1>3 51%</td></tr></table>

<table><tr><td rowspan=2 colspan=1>Range (mg/dL)</td><td rowspan=2 colspan=1>N</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Lot 021075201</td></tr><tr><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>SD(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>20~50 mg/dL</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>55 9</td><td rowspan=1 colspan=1>2 48</td><td rowspan=1 colspan=1>4 44%</td></tr><tr><td rowspan=1 colspan=1>51~110 mg/dL</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>77 5</td><td rowspan=1 colspan=1>2 80</td><td rowspan=1 colspan=1>3 62%</td></tr><tr><td rowspan=1 colspan=1>111~150 mg/dL</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>132 3</td><td rowspan=1 colspan=1>3 27</td><td rowspan=1 colspan=1>247%</td></tr><tr><td rowspan=1 colspan=1>151~250 mg/dL</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>221 2</td><td rowspan=1 colspan=1>5 92</td><td rowspan=1 colspan=1>267%</td></tr><tr><td rowspan=1 colspan=1>251~400 mg/dL</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>368 9</td><td rowspan=1 colspan=1>7 74</td><td rowspan=1 colspan=1>2 10%</td></tr><tr><td rowspan=1 colspan=1>401~600 mg/dL</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>563 4</td><td rowspan=1 colspan=1>13 96</td><td rowspan=1 colspan=1>2 48%</td></tr><tr><td rowspan=1 colspan=1>Normalcontrol solution</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>119 7</td><td rowspan=1 colspan=1>4 38</td><td rowspan=1 colspan=1>3 66%</td></tr></table>

Day-to-Day Precision 10 Meters, 2 lots of test strip, and 3 control solutions of Low, Normal and High were prepared Each control was tested twice a day, once in the morning and once in the afternoon for 10 days $N = 1 0$ Meter $\times 2$ Lots x 2 tests $\yen 10$ days $\tt { \tt = 4 0 0 }$

<table><tr><td rowspan=1 colspan=1>Controlsolution</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>mean(mg/dL)</td><td rowspan=1 colspan=1>SD(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>47 1</td><td rowspan=1 colspan=1>1 67</td><td rowspan=1 colspan=1>3 54%</td></tr><tr><td rowspan=1 colspan=1>Normal</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>122 2</td><td rowspan=1 colspan=1>4 62</td><td rowspan=1 colspan=1>3 78%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>398 5</td><td rowspan=1 colspan=1>10 57</td><td rowspan=1 colspan=1>2 65%</td></tr></table>

b Linearity/assay reportable range

A blood sample of 25 mL was taken, treated with heparin vacuum tube, to be set for a day Testing was performed using whole blood supplemented with $\beta$ -Dglucose to provide samples at seven different blood glucose levels ( $2 0 { \cdot } 5 0 \ m g / \mathrm { d L } .$ 51-80 mg/dL, 81-120 mg/dL, 121-200 mg/dL, 201-300 mg/dL, 301-400 mg/dL, and 400-600 mg/dL) A total of 210 tests were performed using 10 meters among the seven glucose ranges per each strip lot

The linear regression was as follows

<table><tr><td rowspan=1 colspan=1>N=</td><td rowspan=1 colspan=1>630 (210X3Lot)</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>1 0450</td></tr><tr><td rowspan=1 colspan=1>Y-intercept</td><td rowspan=1 colspan=1>-1 2505</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>0 9950</td></tr></table>

C Traceability, Stability, Expected values (controls, calibrators, or methods) The device is traceable to a laboratory YSl 2300D analyzer Calibrate YSI 2300D analyzer before its use and the calibrators are manufactured gravimetrically and provided from the instrument supplier Execute the validation of YSl 2300D analyzer by using this international standard reference material (NIST 965a) every year Stability characteristics of the Normal and High control solutions were determined by using real-time stability studies to determine the storage stability at room temperature to be 19 months

# d Detection limit

Data was provided to support a reportable range of 20-600 mg/dL

# e Analytical specificity

Hematocrit interference was evaluated by adjusting the glucose concentrations and hematocrit levels of venous blood samples from several donors The venous blood samples spiked to 4 glucose concentration levels described in the foliowing table The hematocrit levels were adjusted to $0 \%$ . $20 \%$ , $40 \%$ , $50 \%$ $60 \%$ and $70 \%$ Each sample was run $n = 1 0$ for each strip lot and the maximum percent bias was calculated compared to the 40% hematocrit samples The acceptance criteria of Hematocrit interference test is bias $\leq 1 5 m g / \mathrm { d L }$ when glucose concentration $\$ 75$ mg/dL and bias ≤ 15% when glucose concentration > 75 mg/dL Results are summarized in table as below After analysis of this studie, the claim for the device was for use with samples having hematocrit concentrations ranging from 20% to $60 \%$ EP

<table><tr><td rowspan=2 colspan=1>Strip lot #</td><td rowspan=2 colspan=1>Hematocrit%</td><td rowspan=1 colspan=4>YSI Labeled Value, mg/dL</td><td rowspan=2 colspan=1>Slope</td><td rowspan=2 colspan=1>Y-intercept</td><td rowspan=2 colspan=1>R^{2}$</td><td rowspan=2 colspan=1>% Bias</td></tr><tr><td rowspan=1 colspan=1>Level1</td><td rowspan=1 colspan=1>Level2</td><td rowspan=1 colspan=1>Level3</td><td rowspan=1 colspan=1>Level4</td></tr><tr><td rowspan=6 colspan=1>012072901</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>54 851</td><td rowspan=1 colspan=1>1225</td><td rowspan=1 colspan=1>267 0</td><td rowspan=1 colspan=1>494 0</td><td rowspan=1 colspan=1>0 9874</td><td rowspan=1 colspan=1>51 745</td><td rowspan=1 colspan=1>0 9697</td><td rowspan=1 colspan=1>29 51</td></tr><tr><td rowspan=1 colspan=1>20%</td><td rowspan=1 colspan=1>45 25</td><td rowspan=1 colspan=1>119 5</td><td rowspan=1 colspan=1>269 0</td><td rowspan=1 colspan=1>497 0</td><td rowspan=1 colspan=1>0 9461</td><td rowspan=1 colspan=1>72842</td><td rowspan=1 colspan=1>0 9982</td><td rowspan=1 colspan=1>-118</td></tr><tr><td rowspan=1 colspan=1>40%</td><td rowspan=1 colspan=1>47 55</td><td rowspan=1 colspan=1>127 5</td><td rowspan=1 colspan=1>270 0</td><td rowspan=1 colspan=1>505 5</td><td rowspan=1 colspan=1>0 9896</td><td rowspan=1 colspan=1>-34003</td><td rowspan=1 colspan=1>0 9982</td><td rowspan=1 colspan=1>-221</td></tr><tr><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>47 50</td><td rowspan=1 colspan=1>125 5</td><td rowspan=1 colspan=1>2640</td><td rowspan=1 colspan=1>5040</td><td rowspan=1 colspan=1>0 9529</td><td rowspan=1 colspan=1>-4 1426</td><td rowspan=1 colspan=1>0 9974</td><td rowspan=1 colspan=1>-461</td></tr><tr><td rowspan=1 colspan=1>60%</td><td rowspan=1 colspan=1>50 05</td><td rowspan=1 colspan=1>120 5</td><td rowspan=1 colspan=1>264 5</td><td rowspan=1 colspan=1>509 5</td><td rowspan=1 colspan=1>0 9296</td><td rowspan=1 colspan=1>7 5074</td><td rowspan=1 colspan=1>0 9992</td><td rowspan=1 colspan=1>-047</td></tr><tr><td rowspan=1 colspan=1>70%</td><td rowspan=1 colspan=1>50 55</td><td rowspan=1 colspan=1>1180</td><td rowspan=1 colspan=1>258 5</td><td rowspan=1 colspan=1>505 0</td><td rowspan=1 colspan=1>07149</td><td rowspan=1 colspan=1>17 894</td><td rowspan=1 colspan=1>0 9944</td><td rowspan=1 colspan=1>-1346</td></tr><tr><td rowspan=6 colspan=1>012072701</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>54 85</td><td rowspan=1 colspan=1>1225</td><td rowspan=1 colspan=1>267 0</td><td rowspan=1 colspan=1>494 0</td><td rowspan=1 colspan=1>10812</td><td rowspan=1 colspan=1>43 438</td><td rowspan=1 colspan=1>0 9811</td><td rowspan=1 colspan=1>34 01</td></tr><tr><td rowspan=1 colspan=1>20%</td><td rowspan=1 colspan=1>45 25</td><td rowspan=1 colspan=1>1195</td><td rowspan=1 colspan=1>269 0</td><td rowspan=1 colspan=1>497 0</td><td rowspan=1 colspan=1>0 9400</td><td rowspan=1 colspan=1>8 8823</td><td rowspan=1 colspan=1>0 9968</td><td rowspan=1 colspan=1>-0 45</td></tr><tr><td rowspan=1 colspan=1>40%</td><td rowspan=1 colspan=1>47 55</td><td rowspan=1 colspan=1>1275</td><td rowspan=1 colspan=1>270 0</td><td rowspan=1 colspan=1>505 5</td><td rowspan=1 colspan=1>10130</td><td rowspan=1 colspan=1>-7 8632</td><td rowspan=1 colspan=1>0 9981</td><td rowspan=1 colspan=1>-275</td></tr><tr><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>47 50</td><td rowspan=1 colspan=1>125 5</td><td rowspan=1 colspan=1>264 0</td><td rowspan=1 colspan=1>504 0</td><td rowspan=1 colspan=1>0 9423</td><td rowspan=1 colspan=1>-1 8592</td><td rowspan=1 colspan=1>0 9992</td><td rowspan=1 colspan=1>-3 97</td></tr><tr><td rowspan=1 colspan=1>60%</td><td rowspan=1 colspan=1>50 05</td><td rowspan=1 colspan=1>120 5</td><td rowspan=1 colspan=1>264 5</td><td rowspan=1 colspan=1>509 5</td><td rowspan=1 colspan=1>0 9377</td><td rowspan=1 colspan=1>4 4687</td><td rowspan=1 colspan=1>0 9985</td><td rowspan=1 colspan=1>-0 59</td></tr><tr><td rowspan=1 colspan=1>70%</td><td rowspan=1 colspan=1>50 55</td><td rowspan=1 colspan=1>1180</td><td rowspan=1 colspan=1>258 5</td><td rowspan=1 colspan=1>505 0</td><td rowspan=1 colspan=1>0 6798</td><td rowspan=1 colspan=1>26 641</td><td rowspan=1 colspan=1>0 9973</td><td rowspan=1 colspan=1>-10 74</td></tr></table>

f Assay cut-off N/A

# 2 Comparison studies

a Method comparison with predicate device Site 1,2,3.

Accuracy / Method comparison at sites 1,2,3

A total 156 diabetes patients performed a finger stick and forearm using the EasyPlus mini R2N system at 3 sites A healthcare professional then performed the test on the EasyPlus mini R2N and the YSl 2300 analyzer The range of tested values for these samples was 74 2-486 mg/dL In order to fully cover the measuring range, 9 of the samples were spiked with glucose or allowed to glycolyze The total 165 (156+9) samples ranged in concentration from 32 to 591 mg/dL on the EasyPlus mini R2N SMBG system The distribution of total 165 samples is described as below'

<table><tr><td rowspan=1 colspan=1>Glucoseconcentration</td><td rowspan=1 colspan=1>Number of sample</td><td rowspan=1 colspan=1>% of sample</td></tr><tr><td rowspan=1 colspan=1>&lt;50mg/dL</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>36</td></tr><tr><td rowspan=1 colspan=1>50-80 mg/dL</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>48</td></tr><tr><td rowspan=1 colspan=1>81-120mg/dL</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>29 7</td></tr><tr><td rowspan=1 colspan=1>121-200mg/dL</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>34 5</td></tr><tr><td rowspan=1 colspan=1>201-300mg/dL</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>20 0</td></tr><tr><td rowspan=1 colspan=1>301-400mg/dL</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>&gt;400 mg/dL</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>42</td></tr></table>

Meter versus YSl at each site met the IS0 15197 requirement of ninety-five percent (95 %) of the individual glucose results falling within ±15 mg/dL of the results of the manufacturer's measurement procedure at glucose concentrations for samples $< 7 5$ mg/dL and within t $20 \%$ at glucose concentrations ≥75 mg/dL These results are summarized in the table below

System accuracy results for glucose concentrations < 75 mg/dL   

<table><tr><td rowspan=1 colspan=1>Within ±5mg/dL</td><td rowspan=1 colspan=1>Within ±10mg/dL</td><td rowspan=1 colspan=1>Within ±15mg/dL</td></tr><tr><td rowspan=1 colspan=1>7/8(87 5%)</td><td rowspan=1 colspan=1>7/8(87 5%)</td><td rowspan=1 colspan=1>8/8(100 0%)</td></tr></table>

System accuracy results for glucose concentrations $\gneq$ 75 mg/dL

<table><tr><td rowspan=1 colspan=1>Within ±5%</td><td rowspan=1 colspan=1>Within ±10%</td><td rowspan=1 colspan=1>Within ±15%</td><td rowspan=1 colspan=1>Within ±20%</td></tr><tr><td rowspan=1 colspan=1>56/157(35 67%)</td><td rowspan=1 colspan=1>103/157 (65 61%)</td><td rowspan=1 colspan=1>138/157(87 90%)</td><td rowspan=1 colspan=1>151/157 (96 18%)</td></tr></table>

Method comparison studies were performed by using alternate site testing (AST) samples compared to professional finger stick samples The studies were performed by using professional and participant AST samples take from the forearm

The linear regressions were as follows   

<table><tr><td rowspan=1 colspan=1>Comparison</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Range(mg/dL)</td><td rowspan=1 colspan=1>Range(mg/dL) Slope and Y-intercept</td><td rowspan=1 colspan=1>$R{}$</td></tr><tr><td rowspan=1 colspan=1>Finger vs YSI (professionals)</td><td rowspan=1 colspan=1>156</td><td rowspan=1 colspan=1>74 2-486</td><td rowspan=1 colspan=1>Y=1 0470X-3 9092</td><td rowspan=1 colspan=1>0 9540</td></tr><tr><td rowspan=1 colspan=1>Finger vs YSI (lay users)</td><td rowspan=1 colspan=1>156</td><td rowspan=1 colspan=1>74 2-486</td><td rowspan=1 colspan=1>Y=1 0307X-2 8876</td><td rowspan=1 colspan=1>0 9471</td></tr><tr><td rowspan=1 colspan=1>Thenar vs Finger(professionals)</td><td rowspan=1 colspan=1>156</td><td rowspan=1 colspan=1>71 0-566</td><td rowspan=1 colspan=1>Y=1 0113X+3 2591</td><td rowspan=1 colspan=1>0 9610</td></tr><tr><td rowspan=1 colspan=1>Thenar vs Finger(lay users)</td><td rowspan=1 colspan=1>156</td><td rowspan=1 colspan=1>71 0-566</td><td rowspan=1 colspan=1>Y=1 0072X+6 7177</td><td rowspan=1 colspan=1>0 9539</td></tr><tr><td rowspan=1 colspan=1>Hypothenar vs Finger(professionals)</td><td rowspan=1 colspan=1>156</td><td rowspan=1 colspan=1>71 0-566</td><td rowspan=1 colspan=1>Y=1 0642X-2 7188</td><td rowspan=1 colspan=1>0 9617</td></tr><tr><td rowspan=1 colspan=1>Hypothenar vs Finger(lay users)</td><td rowspan=1 colspan=1>156</td><td rowspan=1 colspan=1>71 0-566</td><td rowspan=1 colspan=1>Y=1 0421X+1 0330</td><td rowspan=1 colspan=1>0 9684</td></tr><tr><td rowspan=1 colspan=1>Forearm vs Finger(professionals)</td><td rowspan=1 colspan=1>156</td><td rowspan=1 colspan=1>71 0-566</td><td rowspan=1 colspan=1>Y=0 9144X+16 121</td><td rowspan=1 colspan=1>0 9448</td></tr><tr><td rowspan=1 colspan=1>Forearm vs Finger (lay users)</td><td rowspan=1 colspan=1>156</td><td rowspan=1 colspan=1>71 0-566</td><td rowspan=1 colspan=1>Y=0 9410X+15 266</td><td rowspan=1 colspan=1>0 9163</td></tr></table>

And compare with predicate device, the linear regressions was as follows EasyPlus mini R2N vs predicate device $\gamma = 1 \ 0 4 3 1 X$ -1 1192, ${ \mathsf { R } } ^ { 2 } { \mathop { = } } 0$ 9785

b Matrix companson N/A

3 Clinical studies

a Clinical Sensitivity N/A   
b Clinical specificity N/A   
C Other clnical supportive data (when a and b are not applicable) see section 2 a

# 5 Expected values/Reference range

Expected blood glucose levels for people without diabetes (refereced from American Diabetes Associations Standards of Medical Care for Patients with Diabetes Mellitus, Diabetes Care, 25(2002), p S37)

Time Before meals or Fasting 2 hour after meals

Range (mg/dL) 70-110 Less than 120

N Proposed Labeling

The labeling is sufficient and it satisfies the requrements of 21 CFR Part 809 10

# 0 Conclusion

The EasyPlus mini R2N Self Monitoring Blood Glucose System has the same intended use and similar technological characteristics as the EasyPlus Self Monitoring Blood Glucose System (k061992) marketed by EPS Bio Technology Corp , Moreover, bench testing contained in the submission demonstrate that any differences in their technological characteristics do not raise any new questions of safety or effectiveness Thus, the EasyPlus mini R2N Self-Monitoring Blood Glucose System is substantially equivalent to the predicate devise

# JAN 2 3 2009

EPS Bio Technology Corp   
c/o Y C Lei   
General Manager   
2F No 49-2, Lane 2, Guang Fu Road, Sec 2   
Hsinchu City, 30071   
Taiwan, RO C

Re k081796 Trade Name EasyPlus min R2N Self-Monitoring Blood Glucose Test System Regulation Number 21 CFR 862 1345 Regulation Name Glucose Test System Regulatory Class Class II Product Codes NBW, CGA, JJX Dated January 9, 2009 Received January 12, 2009

Dear Mr Lei

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantally equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA) You may, therefore, market the device, subject to the general controls provisions of the Act The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration

If yourdevce sclassed (see boventoether class  (Specal Controls)r class I MA), it may be subject to such additional controls Existing major regulatons affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895 In addition, FDA may publish further announcements concerning your device in the Federal Register

Please be advised that FDA's issuance of a substantial equvalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies You must comply with all the Act's requrements, including, but not limited to registration and listing (21 CFR Part 807), labelng (21 CFR Parts 801 and 809), and good manufacturing practice requrements as set forth in the quality systems (QS) regulation (21 CFR Part 820)

Thus letter wll allow you to begin marketng your device as descrbed in your Secton 510(k) The n ul ualeyurv  y marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market

If you desre specific information about the application of labelng requrements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084 Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807 97) You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http //www fda gov/cdrh/dsma/dsmamain html

Sincerely yours,

![](images/7a43c7ac6e3036e16d9031612133318fc0d61ade357bbbfc4a6a21e1109b95f5.jpg)

Courtney C Harper, Ph D   
Acting Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indication for Use

# 510(k) Number (if known) k081796 Device Name EasyPlus min R2N Indication For Use

The EasyPlus min R2N Self Monitoring Blood Glucose Test System The EasyPlus mini R2N Self Monitoring Blood Glucose Test System is intended for the quantitative measurement of glucose in fresh capillary whole blood samples drawn from the fingertips or forearm Testing is done outside the body (In Vitro diagnostic use) It is indcated for use at home (over the counter [OTC]) by persons with dabetes, or in clincal settings by healthcare professionals, as an aid to monitor the effectiveness of diabetes control

The EasyPlus mini R2N Meter   
The EasyPlus mim R2N Meter is intended for the quantitative measurement of glucose in fresh capllary whole blood samples drawn from the fingertips or forearm EasyPlus mini R2N Blood Glucose Test Strips must be used with the EasyPlus min R2N Meter Testing is done outside the body (In Vitro diagnostic use)   
It is indicated for use at home (over the counter [OTC]) by persons with diabetes, or in clinical settings by healthcare professionals, as an aid to monitor the effectiveness of dabetes control J The EasyPlus mini R2N Blood Glucose Test Strips   
The EasyPlus min R2N Blood Glucose Test Strips , are intended for the quantitative measurement of glucose in fresh capillary whole blood samples drawn from the fingertips or forearm EasyPlus min R2N Blood Glucose Test Strips must be used with the EasyPlus min R2N Blood Glucose Meter Testing is done outside the body (In Vitro diagnostic use) They are indicated for use at home (over the counter [OTC]) by persons with diabetes, or in clinical settings by healthcare professionals, as an ad to monitor the effectiveness of dabetes control

The EasyPlus mini R2N Glucose Normal/High Control Solution For use with the EasyPlus mini R2N meter and EasyPlus min R2N Blood Glucose Test Strips as a qualty control check to venfy the accuracy of blood glucose test results

Prescription Use_ V (21 CFR Part 801 Subpart D)

Over the Counter Use V (21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE, CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/8268d1f529e408a12622aab9dda0c8f15706194ef725aa20d2973c9ee95acf37.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety